- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Medicus Pharma to focus SkinJect development on Gorlin syndrome | 2 | Investing.com | ||
| Mo | Medicus Pharma fokussiert SkinJect-Entwicklung auf Gorlin-Syndrom | 6 | Investing.com Deutsch | ||
| Mo | Medicus Pharma Optimizes Portfolio Strategy With High-Value Focus | 1 | Benzinga.com | ||
| Mo | Medicus Pharma Ltd: Medicus Pharma Announces Exclusive Development Focus for SkinJect in Gorlin Syndrome Following Commercial, Clinical and Regulatory Assessment | 190 | GlobeNewswire (Europe) | PHILADELPHIA, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a precision guided, biotech/life sciences company focused on advancing novel and potentially... ► Artikel lesen | |
| 11.09. | Medicus Pharma Ltd. - 8-K, Current Report | 3 | SEC Filings | ||
| 10.09. | Medicus Pharma posts phase 2 study results for skin cancer drug | 2 | Investing.com | ||
| MEDICUS PHARMA Aktie jetzt für 0€ handeln | |||||
| 10.09. | Medicus Pharma Ltd: Medicus Pharma Publishes Abridged Final Phase 2 SkinJect Clinical Study Report (CSR) Results Identifying 200 µg D-MNA Patch as the Lead Development Dose | 2 | GlobeNewswire (USA) | ||
| 08.09. | Medicus Pharma shifts focus to precision oncology with CD228V | 3 | Investing.com | ||
| 08.09. | Medicus Pharma Ltd: Medicus Pharma Advances Transformation into a Precision Oncology-Led Biotechnology Company | 233 | GlobeNewswire (Europe) | PHILADELPHIA, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a precision-guided biotech/life sciences company focused on advancing the clinical... ► Artikel lesen | |
| 03.09. | Medicus Pharma Inks Global Licensing Deal with Pfizer Worth Over $1 Billion | 13 | Benzinga.com | ||
| 03.09. | Pfizer offloads scrapped Seagen ADC to Medicus Pharma in up to $1B+ deal | 33 | FierceBiotech | ||
| 03.09. | Medicus Pharma Ltd. - 8-K, Current Report | 1 | SEC Filings | ||
| 13.08. | Medicus Pharma GAAP EPS of -$0.21 | 5 | Seeking Alpha | ||
| 13.08. | Medicus Pharma Ltd: Medicus Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update | 720 | ACCESS Newswire | Company Highlights Significant Regulatory, Clinical and Strategic Progress Across SkinJect and Teverelix Programs and a Strengthened Financial Position Supporting Continued Pipeline Execution and Expansion... ► Artikel lesen | |
| 12.08. | Medicus Pharma Ltd. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 03.08. | Medicus Pharma names Faisal Mehmud CEO of UK subsidiary Antev | 2 | Investing.com | ||
| 03.08. | Medicus Pharma Ltd: Medicus Pharma Appoints Dr. Faisal Mehmud as Chief Executive Officer of Antev Limited, United Kingdom | 376 | GlobeNewswire (Europe) | PHILADELPHIA, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs... ► Artikel lesen | |
| 31.07. | Medicus Pharma receives UAE approval for endometriosis study | 1 | Investing.com | ||
| 31.07. | Medicus Pharma Ltd: Medicus Pharma Receives UAE Department of Health (DOH) Authorization to proceed with Novel Prospective Genomics Guided Precision Medicine Study Evaluating Teverelix in Women with Endometriosis | 3 | GlobeNewswire (USA) | ||
| 31.07. | EXCLUSIVE: Medicus Pharma Launches Genomics-Guided Endometriosis Study In Abu Dhabi | 1 | Benzinga.com |
1 2 3 4 5 Weiter >>
87 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PFIZER | 25,090 | +1,41 % | JPMORGAN stuft PFIZER INC auf 'Neutral' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Pfizer mit einem Kursziel von 28 US-Dollar auf "Neutral" belassen. Dies schrieb Chris Schott in seinem am Donnerstag vorliegenden... ► Artikel lesen | |
| GILEAD SCIENCES | 134,38 | +1,05 % | Gilead Sciences und Assembly Bio: Kommt am 13. Oktober der Herpes-Paukenschlag? | Bei Gilead Sciences verdichten sich derzeit die Hinweise darauf, dass der Pharmakonzern in den kommenden Jahren das Therapiefeld der Virologie massiv ausbauen und damit die langfristige Abhängigkeit... ► Artikel lesen | |
| ELI LILLY | 1.029,60 | +1,74 % | Novo-Medikament Cagrisema in Studie besser als Lilly-Konkurrenzprodukt | DJ Novo-Medikament Cagrisema in Studie besser als Lilly-Konkurrenzprodukt
Von Elias Schisgall
DOW JONES--Novo Nordisk hat einen Studienerfolg mit seinem Abnehm- und Typ-2-Diabetesmedikament... ► Artikel lesen | |
| VERTEX PHARMACEUTICALS | 456,00 | +0,57 % | Vertex Pharmaceuticals Incorporated: Vertex Announces Positive Results From Phase 2b AMPLIFIED Study of Inaxaplin in Additional Populations of People With APOL1-Mediated Kidney Disease (AMKD) and Completion of Enrollment in the Phase 2/3 AMPLITUDE Trial | In people with AMKD with modest proteinuria, treatment with inaxaplin led to a reduction in urine albumin to creatinine ratio (UACR) of -42.7% at Week 13 compared to baseline - - In people with... ► Artikel lesen | |
| EYEPOINT | 3,300 | +0,61 % | XFRA PV3B: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| QUANTUM BIOPHARMA | 3,260 | -6,16 % | Rodman & Renshaw Initiates Analyst Coverage on Quantum BioPharma with a BUY Rating and US$8 Price Target | TORONTO, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (FRA: 0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of... ► Artikel lesen | |
| LIGAND PHARMACEUTICALS | 264,00 | +0,76 % | Ligand Pharmaceuticals: Ligand and AvenCell Therapeutics Enter Financing Agreement to Advance Pipeline of Next-Generation CAR-T Therapies for Up to $47 Million | JUPITER, Fla., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it has entered into a financing agreement with AvenCell Therapeutics, Inc.... ► Artikel lesen | |
| JAZZ PHARMACEUTICALS | 207,00 | +0,29 % | Goldman Sachs startet Jazz Pharmaceuticals mit Kaufempfehlung | ||
| ACHIEVE LIFE SCIENCES | 6,750 | 0,00 % | Achieve Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Updates | Closed a private placement of up to $354 million, with $180 million upfront and up to $174 million from warrants exercisable prior to and up to 20 trading days following FDA approval Strengthened... ► Artikel lesen | |
| UNITED THERAPEUTICS | 416,80 | -3,02 % | United Therapeutics, Sagimet drop after Goldman Sachs Sell ratings | ||
| ROYALTY PHARMA | 50,01 | -1,28 % | EQS-Adhoc: BRAIN Biotech AG: BRAIN Biotech erhält von Royalty Pharma eine bedeutende Meilensteinzahlung in Höhe von 11,51 Millionen Euro | EQS-Ad-hoc: BRAIN Biotech AG / Schlagwort(e): Bedeutende Verträge/Sonstiges
BRAIN Biotech AG erhält von Royalty Pharma eine bedeutende Meilensteinzahlung in Höhe von 11... ► Artikel lesen | |
| OPKO HEALTH | 1,510 | +1,34 % | OPKO Health, Inc.: OPKO Health Expands Strategic Relationship with HealthCare Royalty Through $125 Million Notes Issuance Secured by Mazdutide Royalty Interests | MIAMI, Fla., Aug. 13, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced the expansion of its financing relationship with HealthCare Royalty, a business of KKR (HCRx), through... ► Artikel lesen | |
| JAGUAR HEALTH | 6,210 | -30,30 % | XFRA NEW INSTRUMENTS AVAILABLE ON 17.09.2026 | The following instruments on XETRA do have their first trading 17.09.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 17.09.2026
Aktien
1 CNE100007DY4 Shenzhen Woer Heat-Shrinkable... ► Artikel lesen | |
| CATALYST PHARMACEUTICALS | 27,300 | +2,63 % | Angelini Pharma Completes Acquisition of Catalyst Pharmaceuticals | The Italian pharma company grows its presence in the U.S. market and strengthens its global leadership in Brain Health and Rare DiseasesCompletion of the transaction gives Angelini Pharma ownership... ► Artikel lesen | |
| BRIDGEBIO PHARMA | 57,03 | -1,23 % | BridgeBio auf dem Bernstein Healthcare Forum: Wachstumskurs mit vier Schlüsselprodukten |
Das Unternehmen MEDICUS PHARMA LTD kann der Branche Pharma zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,003 (+1,76 %) liegt der Kurs bei 0,162 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MEDICUS PHARMA LTD finden Sie auf Wallstreet Online.